IOVA
Iovance Biotherapeutics, Inc. Healthcare - Biotechnology Investor Relations →
Iovance Biotherapeutics, Inc. (IOVA) closed at $2.53 as of 2026-02-02, trading 64.8% below its 200-week moving average of $7.18. This places IOVA in the extreme value zone. The stock moved further from the line this week, up from -64.9% last week. The 14-week RSI sits at 60, indicating neutral momentum.
Over the past 751 weeks of data, IOVA has crossed below its 200-week moving average 16 times. On average, these episodes lasted 32 weeks. Historically, investors who bought IOVA at the start of these episodes saw an average one-year return of +27.6%.
With a market cap of $1004 million, IOVA is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -53.9%. The stock trades at 1.4x book value.
Share count has increased 94.4% over three years, indicating dilution.
Over the past 14.5 years, a hypothetical investment of $100 in IOVA would have grown to $2, compared to $790 for the S&P 500. IOVA has returned -22.4% annualized vs 15.3% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Growth of $100: IOVA vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After IOVA Crosses Below the Line?
Across 16 historical episodes, buying IOVA when it crossed below its 200-week moving average produced an average return of +19.0% after 12 months (median +26.0%), compared to +14.8% for the S&P 500 over the same periods. 56% of those episodes were profitable after one year. After 24 months, the average return was +56.9% vs +29.4% for the index.
Each line shows $100 invested at the moment IOVA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
IOVA has crossed below its 200-week MA 16 times with an average 1-year return of +27.6% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Sep 2011 | Oct 2011 | 5 | 19.0% | -72.2% | -97.4% |
| Nov 2011 | Feb 2012 | 11 | 21.9% | -66.1% | -97.7% |
| Feb 2012 | Apr 2012 | 6 | 12.9% | -93.2% | -97.8% |
| Apr 2012 | Jul 2016 | 222 | 98.8% | -97.6% | -97.0% |
| Oct 2016 | Nov 2016 | 4 | 18.4% | +15.0% | -60.2% |
| Nov 2016 | Dec 2016 | 2 | 14.7% | +46.7% | -57.8% |
| Dec 2016 | Jan 2017 | 1 | 1.0% | +15.1% | -63.6% |
| Jan 2017 | Jan 2017 | 1 | 0.9% | +95.7% | -63.9% |
| Apr 2017 | Sep 2017 | 23 | 36.5% | +111.5% | -61.4% |
| Oct 2017 | Oct 2017 | 3 | 2.6% | +63.4% | -65.3% |
| Oct 2018 | Nov 2018 | 3 | 0.6% | +127.9% | -71.9% |
| Dec 2018 | Dec 2018 | 4 | 17.1% | +175.6% | -71.8% |
| Jan 2019 | Jan 2019 | 1 | 0.4% | +148.0% | -71.8% |
| May 2021 | Jun 2021 | 3 | 16.0% | -14.5% | -86.0% |
| Aug 2021 | Aug 2021 | 2 | 5.0% | -41.8% | -88.4% |
| Nov 2021 | Ongoing | 222+ | 84.3% | Ongoing | -88.0% |
| Average | 32 | — | +27.6% | — |
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of Friday close, 2026-02-02